drugset
drugset / Trial / NCT04735536

Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG

NCT04735536 ↗

Phase 2 Completed 16 enrolled Cognition Therapeutics National Institute on Aging (NIA) · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.

Timeline

Start
2020-07-09
Primary completion
2023-04-26
Completion
2023-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject CT1812 Small molecule 300 mg —

Indications

Alzheimer disease